Professor of Pathology and Laboratory Medicine
|1982-1986||B.A.||Psychobiology||Wheaton College, Norton MA|
|2006||M.A.||Brown University (ad eundem)|
|1986-1991||Ph.D.||Biology (Reproductive Endocrinology)||Boston University, MA|
Geralyn Lambert-Messerlian PhD, FACB earned her degree in Endocrinology at Boston University and completed her post-doctoral training in Reproductive Endocrinology at the Massachusetts General Hospital/Harvard University. She currently serves as Director of Medical Screening and Special Testing at Women and Infants Hospital and Professor of Pathology and Laboratory Medicine at the Alpert Medical School of Brown University. She is also Co-Director of the Center for Biomarkers and Emerging Technologies. Her research is focused on the development and application of serum biomarkers for women’s health, particularly in the areas of fertility, pregnancy and gynecologic cancers.
Development and application of serum biomarkers for women’s health, particularly in the areas of fertility, pregnancy and gynecologic cancers.
|1994-1995||Instructor in Medicine||Harvard University|
|1995-1999||Assistant Professor (Research)||Pathology and Laboratory Medicine||Alpert Medical School of Brown University|
|2000-2004||Assistant Professor||Pathology and Laboratory Medicine||Alpert Medical School of Brown University|
|2005-2010||Associate Professor||Pathology and Laboratory Medicine||Alpert Medical School of Brown University|
|2011||Professor||Pathology and Laboratory Medicine||Alpert Medical School of Brown University|
|2016||Professor||Obstetrics and Gynecology||Alpert Medical School of Brown University|
|1994-1995||Assistant in Biochemistry||Reproductive Endocrine Unit||Massachusetts General Hospital|
|1995-1999||Assistant Director||Division of Prenatal and Special Testing||Women and Infants Hospital|
|2000-2012||Associate Director||Division of Medical Screening and Special Testing||Women and Infants Hospital|
|2007||Institutional Review Board for Human Studies||Women and Infants Hospital|
|2010||Associate Director||Department of Obstetrics and Gynecology||Center for Biomarkers and Emerging Technologies (CBET)|
|2010-2012||Research Steering Committee (S2N/T2)||Women and Infants Hospital|
|2013||Library Committee for Medical Staff Office||Women and Infants Hospital|
|2013||Director||Division of Medical Screening and Special Testing||Women and Infants Hospital|
|2014||Assistant Director||Division of Chemistry||Women and Infants Hospital|
- Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF Jr and Schneyer AL. Relatively low levels of dimeric inhibin in men and women with PCOS using a specific two-site ELISA. J Clin Endocrinol Metab, 79(1): 45-50, 1994.
- Seifer DB, Lambert-Messerlian GM, Canick JA, Frishman GN and Schneyer AL. Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies. Fertil Steril, 65(3): 667-669, 1996.
- Lambert-Messerlian GM, Palomaki GE, Schneyer AL and Canick JA. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor and activin in Down syndrome pregnancy, J Med Screen, 3: 58-62, 1996.
- Zheng W, Sung CJ, Hanna I, Depetros G, Lambert-Messerlian G, Steinhoff M and Lauchlan SC. Alpha and betaA subunits of inhibin/activin as sex-cord-stromal differentiation markers. Int J Gynecol Path, 16: 263-271,1997.
- Seifer DB, Lambert-Messerlian GM, Hogan JW, Gardiner AC, Blazar AS and Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril, 67: 110-114, 1997.
- Welt CK, Martin KA, Taylor AE, Lambert-Messerlian GM, Crowley WF Jr., Smith JA, Schoenfeld DA and Hall JE. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women. J Clin Endocrinol Metab, 82: 2645-2652, 1997.
- Silver HM, Lambert-Messerlian GM, Star JA, Hogan J and Canick JA. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic and non-proteinuric gestational hypertensive pregnancy. Am J Obstet Gynecol, 180:1131-1137, 1999.
- Lambert-Messerlian GM, Silver H, Petraglia F, Luisi S, Plaino L, Maybruck W, Hogge WA and Canick JA. Second trimester maternal serum levels of inhibin A and human chorionic gonadotropin as markers for prediction of preeclampsia. J Soc Gynecol Investig, 7:170-174, 2000.
- DePasquale S, Lambert-Messerlian G, Quddus MR, Campbell I, Steinhoff M, Gajewski W, Granai C, Tantravahi U. Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. Int J Gynecol Cancer, 12:443-447, 2002.
- Lee T, LeShane ES, Messerlian GM, Canick JA, Farina A, Heber WW, Bianchi DW. Down syndrome and cell-free fetal DNA in archived maternal serum. Am J Obstet Gynecol, 187:1217-21, 2002.
- Thirunavukarasu PP, Lambert-Messerlian G, Robertson DM, Dawson G, Canick J, Wallace EM. Molecular weight forms of inhibin A, inhibin B and pro-alphaC in maternal serum, amniotic fluid and placental extracts of normal and Down syndrome pregnancies. Prenat Diagn, 22 (12):1086-92, 2002.
- Farina A, LeShane E, Lee T, Lambert-Messerlian GM, Canick JA, Bianchi DW. Performance of cell-free fetal DNA as a second trimester maternal serum marker of Down syndrome pregnancy. Clin Chem, 49(2): 2003.
- Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer AL, Canick JA. Inhibins and activins in human fetal abnormalities. Mol Cell Endocrinol, 225(1-2):101-8, 2004.
- Wataganara T, Peter I, Messerlian GM, Borgatta L, Bianchi DW. Inverse correlation between maternal weight and second trimester circulating cell-free fetal DNA levels. Obstet Gynecol, 104(3):545-50, 2004.
- Lambert-Messerlian GM, Canick JA. Placenta growth factor levels in second trimester maternal serum from pregnancies affected with Down syndrome and in prediction of preeclampsia. Prenat Diagn, 24: 876-880, 2004.
- Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Hackshaw AK, Lambert-Messerlian G, D’Alton ME for the FASTER Research Consortium* First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER): Principal Results of the NICHD Multicenter Down Syndrome Screening Study. N Engl J Med, 353(19): 2001-11, Nov 2005.
- Silberstein T, MacLaughlin DT, Shai I, Trimarchi JB, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar A. Mullerian inhibitory substance levels at the time of hCG administration in IVF cycles predict both ovarian reserve and embryo quality. Hum Reprod, 21(1)159-163, Jan 2006.
- Lambert-Messerlian G, Eklund E, Malone F, Canick J, Palomaki G, D’Alton M and the FASTER research consortium. Stability of first and second trimester serum markers after shipment. Prenat Diagn, 26(1):17-21, Jan, 2006.
- Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, Disilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108: 402-8, Feb 2008.
- Lambert-Messerlian G, Palomaki GE, Canick JA. Adjustment of serum markers in first trimester screening. J Med Screen, 16:102-3, 2009.
- Zhang J, Lambert-Messerlian G, Palomaki GE, Canick JA. Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters. Prenat Diagn. Jun; 31(6):583-8, 2011.
- Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. Oct 14; 913-20, 2011.
- Lambert-Messerlian G, Kloza EM, Williams J 3rd, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, De Biasio P, Borrell A, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE. Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies. Genet Med. 16(5):419-22 May 2014.
- Lambert-Messerlian G, Plante B, Eklund E, Raker C and Moore RG. Levels of anti-Müllerian hormone (AMH) in serum during the normal menstrual cycle. Fertility and Sterility, 105: 208-13, Jan 2016.